
Addressing unmet medical needs
Chronic diseases cause suffering for billions of people and cost trillions of dollars to treat every year.
The challenge for biopharma and healthcare is to understand which targets and drugs will work with which subgroups of patients.
We're a pioneering techbio company generating the deepest insights and IP in complex chronic diseases to unlock precision drug discovery and development.
.jpg)
>80%
of healthcare spending is on chronic diseases
90%
of drug programs failed in the last decade
57%
of phase III trial failures due to lack of efficacy
Understanding disease biology better
The era of precision medicine is here.
We identify, target, and treat the biological mechanisms driving disease within subgroups of patients, developing mechanistic patient stratification biomarkers to derisk biopharma innovation.
We've delivered the deepest disease insights in complex, chronic indications generating the largest pipeline novel drug targets and repositioning opportunities outside of major pharma.
Stratifying patient populations
We find more signal in patient data than anyone else.
Our high-resolution patient stratification identifies subgroups of patients with similar disease drivers and treatment responses, to make precision medicine possible in chronic diseases.
We discover new drug targets, enrich clinical trials, find drug repositioning opportunities, and inform better diagnosis and the prescription of more effective therapies.


Driving precision medicine
Our AI-led Innovation Engine, powered by our unique combinatorial analytics, stratifies patient populations at the highest resolution, finding all the mechanistic drivers of disease for subgroups of patients.
With these insights we are:
✔ Discovering novel drug targets and leads for unmet medical needs
✔ Identifying drug repositioning candidates for patient subgroups
✔ Enriching clinical trials and rescuing shelved programs
✔ Designing more accurate diagnostic and clinical decision support tools
✔ Predicting and preventing chronic disease in patients
